Aptevo ended 2025 with $21.6 million in cash and cash equivalents, compared with $8.7 million at December 31, 2024, and expects current resources to support operations into the fourth quarter of 2026. In 2026, the Company established a $60 million equity line facility, providing additional access to capital, subject to market conditions and the Company’s capital deployment strategy. If fully utilized, this facility, together with current resources, is expected to support operations into 2029.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APVO:
- Aptevo Reports Promising Interim Data for AML Therapy
- Aptevo Therapeutics announces interim data for mipletamig combination
- Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity
- Aptevo Therapeutics Announces CEO Transition and Leadership Changes
- Aptevo Therapeutics CEO Marvin White to retire, assume Executive Chair role